LIQUID BIOPSY EGFR TRUE

A liquid biopsy test focused on detecting mutations in the EGFR gene, which are associated with non-small cell lung cancer. It helps in the personalized treatment of lung cancer.

Also known asLiquid Biopsy-egfr True Liquid Biopsy-egfr True

Available via

Home Collection, Lab Visit

Contains

7 parameters

Earliest reports in

8 Working Days

Test details

LIQUID BIOPSY EGFR TRUE Test in Mangaluru Overview

What is Liquid Biopsy EGFR True test?

Liquid Biopsy EGFR True test analyzes a patient's blood sample to identify genetic mutations in the Epidermal Growth Factor Receptor (EGFR) gene, primarily for non-small cell lung cancer (NSCLC). This test helps determine if a patient's cancer is susceptible to certain tyrosine kinase inhibitor (TKI) drugs, enabling personalized treatment plans and improved patient outcomes. This test identifies mutations in the EGFR gene, which can influence treatment decisions for lung cancer and other tumors

Why consider Liquid Biopsy EGFR True test?

Liquid Biopsy EGFR True test identifies specific genetic changes (EGFR mutations) in tumor cells that predict sensitivity to targeted therapies called EGFR tyrosine kinase inhibitors (TKIs).

  • Guides Targeted Therapy
  • Personalized Treatment
  • Detects Resistance Mutations

Who should get this Liquid Biopsy EGFR True test?

Liquid Biopsy EGFR True test is recommended by clinicians for

  • Patients primarily those with newly diagnosed non-small cell lung cancer (NSCLC), especially adenocarcinoma, to determine if their tumor has an EGFR gene mutation
  • Patients with advanced NSCLC, especially adenocarcinoma or NSCLC‑NOS with adenocarcinoma features, as part of standard biomarker workup regardless of age, sex, or smoking history.
  • Cases with sufficient tumor in FFPE blocks or slides; cytology cell blocks can also be suitable when tissue is limited, per lab validation.

More Information about Liquid Biopsy EGFR True test

EGFR mutation refers to a change in the epidermal growth factor receptor gene that causes continuous activation of its tyrosine kinase signaling, driving tumor growth, most commonly in non‑small cell lung cancer (NSCLC). The two most common mutations are exon 19 deletions and the exon 21 L858R point mutation, together accounting for about 85–90% of EGFR mutations in NSCLC.

Other Names: EGFR Mutation Analysis, EGFR Exon 18–21 Analysis; EGFR Molecular Testing, EGFR mutation test on blood, Liquid biopsy EGFR test

Preparations

No special preparations needed

Test included
LIQUID BIOPSY EGFR TRUE includes 7 parameters

  • Exon 18 G719x Mutation
  • Exon 19 Deletions
  • Exon 20 S768i Mutation
  • Exon 20 T790m Mutation
  • Exon 20 Insertions
  • Exon 21 L858r Mutation
  • Exon 21 L861q Mutation

Test code

RD1514

Specimen vol. and vacutainer information
SpecimenVacutainerVolume
Plasma EdtaLavender Vacutainer

Specimen stability information

Plasma Edta

Collection instructions

Clinical History

Specimen rejection criteria

Test run frequency

Every Day TIME - 10:00

Turn around time

8 Working Days

Performing locations

Department

  • Advanced Molecular Diagnostics R&d

CPT and Loinc codes

LIQUID BIOPSY EGFR TRUE

15000